Medications Biohaven Receives FDA May Proceed Letter For Phase 3 Clinical Trial Of BHV-3241 For Multiple System Atrophy 01/29/2019 NEW HAVEN, Conn., Jan. 23, 2019 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today the U.S. Food and Drug Administration (FDA) has notified the Read More